Radiation-Free Immunotherapy Approach Offers Hope for Locally Advanced Lung Cancer

A small study from Japan suggests pembrolizumab and chemotherapy alone may sustain strong survival outcomes in select PD-L1–high NSCLC patients

In patients with unresectable, locally advanced non–small cell lung cancer (NSCLC) showing high PD-L1 expression, a radiation-free combination of pembrolizumab (Keytruda) and platinum-based chemotherapy achieved a 67% two-year progression-free survival rate and 81% overall survival, with manageable toxicity.

Study Details

Researchers at the Kobe Minimally…